← Back to Search

Subjects successfully implanted with an Abbott Assert-IQ ICM device for Atrial Fibrillation (Assert-IQ Trial)

N/A
Recruiting
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up holter monitor worn by the subjects over a minimum 72-hour and up to 7 days period. an af episode is defined as af has greater or equal to 2 minutes (≥2 minutes) in duration.
Awards & highlights

Assert-IQ Trial Summary

This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.

Eligible Conditions
  • Atrial Fibrillation
  • Arrhythmia
  • Ablation

Assert-IQ Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~holter monitor worn by the subjects over a minimum 72-hour and up to 7 days period. an af episode is defined as af has greater or equal to 2 minutes (≥2 minutes) in duration.
This trial's timeline: 3 weeks for screening, Varies for treatment, and holter monitor worn by the subjects over a minimum 72-hour and up to 7 days period. an af episode is defined as af has greater or equal to 2 minutes (≥2 minutes) in duration. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Episode-based AF detection performance metrics

Assert-IQ Trial Design

1Treatment groups
Experimental Treatment
Group I: Subjects successfully implanted with an Abbott Assert-IQ ICM deviceExperimental Treatment1 Intervention
Holter monitoring in subjects successfully implanted with an Abbott Assert-IQ ICM device

Find a Location

Who is running the clinical trial?

Abbott Medical DevicesLead Sponsor
638 Previous Clinical Trials
404,038 Total Patients Enrolled
75 Trials studying Atrial Fibrillation
31,836 Patients Enrolled for Atrial Fibrillation
Kwangdeok Lee, PhDStudy DirectorAbbott

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~100 spots leftby Oct 2024